NINJA JOINS LA ROCHE-POSAY AS NEW PARTNER IN CAUSE FOR SKIN CANCER DETECTION AND PREVENTION
This unprecedented collaboration comes a year after the 33 years old global icon shared with the world his melanoma diagnosis which was revealed during his annual mole check with a dermatologist.
"By sharing my personal experience far beyond my community, through the campaign with La Roche-Posay, I want to deliver a crucial message about skin cancer prevention: don't play games with detection," said Tyler "NINJA" Blevins, pro-gamer and melanoma survivor.
With an engaged and passionate fanbase across multiple digital platforms, NINJA has transcended the gaming industry, bringing an inclusive and powerful message that resonates with audiences globally.
Tyler "NINJA" Blevins embodies La Roche-Posay's core values of authenticity and transparency, anchoring this cause across multiple generations.
"Together, NINJA and La Roche-Posay are ushering in a new era of skin cancer awareness. With cases rising at an alarming rate,our mission is clear: to educate people about the importance of annual mole checks so that melanoma remains 99% preventable and treatable, especially among younger generations," said Alexandra Reni-Catherine, Global Brand General Manager for La Roche-Posay.
SAVE YOUR SKIN PROGRAMTo ensure a healthier future for all, La Roche-Posay has committed more than 20 years of research and awareness driving campaigns on the prevention and detection of skin cancer. With global initiatives in place to offer annual free mole checks in various communities and education campaigns with Dermatologists on sun safety habits, and self-detection via the ABCDE method. La Roche-Posay remains at the forefront of skin cancer awareness.
40%1 is the projected increase in melanoma rates for today's children by 2040.
99%2 of melanomas are curable if detected early.
70%3 of the population doesn't understand the difference between UVA which penetrates deep and causes aging and UVB which affects the surface and causes sunburn.
80%4 of the total lifetime UV exposure is received before the age of 18.
12%5 only of the global population systematically uses all protective measures during exposure.
200K free mole checks were offered by La Roche-Posay in 2024.
The Save your Skin campaign with NINJA will be launched during the EADV Congress in September 2025 in Paris.
For additional information about La Roche-Posay, visit www.laroche-posay.com and follow La Roche-Posay on Instagram, Tiktok, YouTube and Facebook.
ABOUT LA ROCHE-POSAYIn 2025, La Roche-Posay celebrates 50 years of life-changing dermatological skincare solutions. Created by a pharmacist in 1975, the brand is now present in over 60 countries and is recommended by 100,000 dermatologists worldwide. It provides a unique range of daily skincare developed for every skin type, from newborns to cancer patients, from UV protection to repairing severely fragilized skin.
1 Arnold et al. JAMA Dermatol. 2022;158(5)2 www.skincancer.org3 Passeron. J Eur Acad Dermatol Venereol. 2023;374 Raymond-Lezman JR, Riskin S. Attitudes, Behaviors, and Risks of Sun Protection. Cureus. 2023;15(2):e34934.5 Passeron. J Eur Acad Dermatol Venereol. 2023;37
View original content to download multimedia:https://www.prnewswire.com/news-releases/ninja-joins-la-roche-posay-as-new-partner-in-cause-for-skin-cancer-detection-and-prevention-302408336.html
SOURCE La Roche-Posay
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Xtalks Announces its Life Science Webinar Calendar for August 2025
Upcoming free, educational webinars from Xtalks will feature topics on cell and gene therapy, clinical trials, commercialization & HEOR, drug discovery & development, healthcare, laboratory technology, medical device, patient recruitment & retention, pharma manufacturing & supply chain and preclinical. TORONTO, Aug. 1, 2025 /PRNewswire/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries. Access to all webinars is free, so be sure to register today to save your place! Participate in the discussion and stay relevant in your field! Visit to see our upcoming webinars: CELL AND GENE THERAPYAugust 22 - How Cell-Free mRNA Templates Support Faster Research with High-Quality and Quick Turnaround CLINICAL TRIALSAugust 7 - Improving Clinical Tech Adoption: Site-Centric ApproachesAugust 13 - Accelerating Clinical Research with Master Protocols: Challenges and Benefits to Complex Trial DesignsAugust 14 - Designing Innovative Trials: Navigating Dose Optimization in Oncology CombinationsAugust 15 - AI in Clinical Trials: Early Use Cases and Innovations COMMERCIALIZATION & HEORAugust 19 - 5 Critical Questions to Ask Before Applying AI to Real-World Data DRUG DISCOVERY & DEVELOPMENTAugust 7 - Oral Dosage Innovation for Pediatric Drug DeliveryAugust 7 - Cancer Drug Discovery: A Synthetic Lethality Approach Using Integrated PlatformsAugust 12 - Radiotracers and ADC Targeting: Scientific Insights for In Vivo Validation and Clinical TransitionAugust 13 - AI in Drug Discovery & Development: Hype, Reality and What Comes NextAugust 21 - Dose Escalation: Optimizing Cohort Management in Early-Phase DevelopmentAugust 26 - AI in Bioprocessing Today — Accelerate. Predict. Deliver. HEALTHCAREAugust 20 - Beyond Diagnosis: The Real-World Impact of AVISE Testing on Lupus, Rheumatoid Arthritis, and Autoimmune Disease Care LABORATORY TECHNOLOGYAugust 6 - Precision Matters: The Critical Role of Accurate Liquid Handling in the Lab MEDICAL DEVICEAugust 25 - Transforming Medical Imaging with AI: Open Tools, Faster Insights PATIENT RECRUITMENT & RETENTIONAugust 20 - Transforming Patient Recruitment: AI and Digital Strategies to Engage the Unreachable 95%August 27 - Enhancing Patient Recruitment in Clinical Research: A Personalized and Engaged Journey PHARMA MANUFACTURING & SUPPLY CHAINAugust 14 - Biofermentation Success Through pH and DO Management PRECLINICALAugust 26 - Advanced In Vivo Efficacy Models for Preclinical Success ABOUT XTALKS Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers. To learn more about Xtalks visit Contact:Ayesha RashidXtalks ( Tel: +1 (416) 977-6555 x371Email: arashid@ View original content to download multimedia: SOURCE Xtalks Inicia sesión para acceder a tu cartera de valores
Yahoo
4 hours ago
- Yahoo
OSR Holdings to Host Virtual Investor Event Providing Key Corporate Updates and Strategic Direction on August 6, 2025
BELLEVUE, Wash., Aug. 1, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical innovations to improve health and wellness worldwide, today announced that it will host a Virtual Investor Event on Wednesday, August 6, 2025 at 8:00 a.m. Eastern Time (2:00 p.m. Central European Summer Time / 9:00 p.m. Korea Standard Time). The event will provide shareholders and prospective investors with a detailed update of the Company's strategic direction, subsidiary performance, capital allocation, and pipeline R&D. Senior members of the OSRH executive team will be presenting. Event Details Date: Wednesday, August 6, 2025Time: 8:00 a.m. ET / 2:00 p.m. CEST / 9:00 p.m. KSTLocation: Virtual (livestream access)Registration: Opens Monday, August 4 at Available after the event on the OSR Holdings Investor Relations website. Agenda Highlights Corporate overview and strategic vision Subsidiary and R&D pipeline updates: Vaximm: Tailored, Antigen-specific in vivo T-cell Immunotherapies Darnatein: DRT101 – a potent DMOAD candidate Woori IO acquisition: The opportunity for noninvasive CGM Equity Line of Credit (ELOC) financing strategy Blockchain & Tokenization strategy Live Q&A with management "This event is a timely opportunity to engage with our shareholders and the broader investment community as we move into a transformative stage in OSR's growth," said Peter Hwang, CEO of OSRH. "We look forward to showcasing the strength of our platform, the progress we've made, and the catalysts ahead. We are committed to transparency, disciplined execution, and delivering meaningful value to all stakeholders in the coming months."Featured Speakers: Mr. Peter Hwang – Chief Executive Officer Dr. Constance Höfer – Chief Scientific Officer Mr. Tim Smith – Global Investor Relations About OSR Holdings, Inc. OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness to support global health outcomes. Through its subsidiaries, OSRH is engaged in immuno‑oncology, regenerative biologics, and medical device distribution. OSRH's vision is to acquire and operate a portfolio of innovative healthcare and wellness companies, improving patient care through cutting‑edge research and development. For more information, visit View original content to download multimedia: SOURCE OSR Holdings Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
6 hours ago
- Yahoo
Prince and Princess of Wales 'consider leaving Adelaide Cottage'
The Prince and Princess of Wales are reportedly considering moving from Adelaide Cottage. The royal couple have lived in the grounds of Windsor Castle for the last three years, but they are now considering relocating to somewhere bigger, with Fort Belvedere - which is located in Windsor Great Park - being tipped as one possible destination. A source told the Mail on Sunday newspaper: "They feel they have outgrown Adelaide Cottage and need somewhere more substantial. "This is the perfect new home for them. It has a swimming pool and tennis court, and Charlotte loves playing tennis." The Prince and Princess of Wales - who have Prince George, 12, Princess Charlotte, ten, and Prince Louis, seven, together - are currently evaluating their options, but no move is imminent. Earlier this year, the Princess announced that she was in remission from cancer. The 43-year-old royal took to social media in January to reflect on her emotional return to the Royal Marsden Hospital in west London, where she received treatment for cancer, and to confirm that she was in remission from the disease. Catherine - who went public with her cancer diagnosis in March 2024 - wrote on X: "I wanted to take the opportunity to say thank you to The Royal Marsden for looking after me so well during the past year. "My heartfelt thanks goes to all those who have quietly walked alongside William and me as we have navigated everything. "We couldn't have asked for more. The care and advice we have received throughout my time as a patient has been exceptional. "In my new role as Joint Patron of The Royal Marsden, my hope is, that by supporting groundbreaking research and clinical excellence, as well as promoting patient and family wellbeing, we might save many more lives, and transform the experience of all those impacted by cancer. "It is a relief to now be in remission and I remain focussed on recovery. As anyone who has experienced a cancer diagnosis will know, it takes time to adjust to a new normal. I am however looking forward to a fulfilling year ahead. There is much to look forward to. Thank you to everyone for your continued support. C (sic)"
